Infectious and Rare Diseases
Overview of the global anticoagulant market
Technavio’s market research analyst predicts the global anticoagulant market to grow steadily at a CAGR of above 7% by 2021. One of the primary drivers for this market is the rise in demand for novel oral anticoagulants (NOACs). NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin. Moreover, the introduction of anticoagulant antidotes in 2015 such as idarucizumab into the market is expected to increase the acceptance of NOACs, as the risk of bleeding will be eradicated. Consequently, this will propel the growth of the global anticoagulant market during the forecast period.
In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The Americas market is growing at a significant growth pace with the introduction of NOACs. The warfarin showed high growth when compared with the oral anticoagulant. However, the revenue generated from the sales of warfarin is low due to the availability of generics, which are available at significantly lower prices. With vitamin K antagonists taking over the share of factor Xa inhibitors and DTIs, the Americas is expected to dominate to global anticoagulant market for the coming few years.
Competitive landscape and key vendors
The global anticoagulant market is highly competitive due to the presence of several international and regional vendors. The market has observed a high growth because of the increase in usage of NOACs and the growing number of surgeries
Global outlook of the tuberculosis (TB) drug market
Technavio’s market research analysts predict the global tuberculosis drug market to grow steadily during the forecast period and post a CAGR of more than 3% by 2021. This industry research report identifies the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains to be one of the major factors that will have a positive impact on the growth of this market in the coming years. The recent years witnessed an increase in the emergence of drug-resistant TB, especially in the highly populated countries such as India and China. It has been observed by the Centers for Disease Control and Prevention (CDC) that XDR-TB is present across all regions of the world and is most prevalent in countries of the former Soviet Union and Asia. Countries such as the US, India, Japan are also witnessing an increase in the transmission of MDR-TB. This increase in TB infections will subsequently drive the demand for TB drugs in the coming years, in turn, aiding market growth.
This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the TB drugs market throughout the predicted period. Due to factors such as the reduction or stagnant funding for TB prevention efforts in the US, major states such as California, Florida, New York, and Texas reported an increase in the incidence rate of tuberculosis during 2015. This growing incidence rate of TB in the region will be the primary factor for the growth of the market in the Americas.
Competitive landscape and key vendors
The market is oligopoly in nature since there are a very few players who manufacture drugs for tuberculosis and is dominated by the major players such as Sanofi, Otsuka
Overview of the global antifungal drugs market
Market research analysts at Technavio predict that the global antifungal drugs market will grow steadily during the next four years and post a CAGR of more than 3% by 2021. This market research analysis identifies the rising popularity of the over-the-counter (OTC) antifungal drugs for dermal infections as one of the primary growth factors for this antifungal medication market. With extensive advertisements and endorsements pharmaceutical companies are introducing several OTC drugs in the market for the treatment of dermal infections. These OTC drugs are cost-effective and are available as solutions, ointments, creams, powders, lotions, and aerosols. Since these OTC topical antifungal agents, including miconazole nitrate, butenafine hydrochloride, clotrimazole, tolnaftate, and terbinafine hydrochloride are effective in the treatment of mild to moderate fungal skin infections, the coming years will witness an exponential increase in the demand for antifungal medicines.
This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the antifungal pills market throughout the predicted period. The increasing incidences of infectious diseases in the US and the introduction of regulations that support the development of antifungal drugs in the Latin American countries will be the major factors driving the growth of the market in the coming years.
Competitive landscape and key vendors
The market is characterized by the presence of a number of antifungal drugs manufacturers and appears to be highly fragmented. The market is highly competitive and is dominated by the major
Overview of the global atopic dermatitis drugs market
The global atopic dermatitis drugs market is anticipated to grow at a steady rate and will post a CAGR of more than 4% during the forecast period. The growing prevalence of food allergies exacerbating atopic dermatitis will drive the growth prospects for the global atopic dermatitis drugs market in the forthcoming years. According to the industry research report, almost one-third of the children with atopic dermatitis are diagnosed with food allergy. For instance, according to research studies, 5%-10% of all children have atopic dermatitis, and one-third of them have a food allergy. One of the major factors responsible for the growing risk of severe atopic dermatitis in infancy is related to food sensitization, which is commonly associated with food allergy. It has been observed that these allergies mainly result from the cow’s milk, chicken eggs, peanuts, wheat, soy, nuts, and fish.
The launch of the first biologic for atopic dermatitis will drive the market prospects for the global atopic dermatitis drugs market for the next four years. Biologic agents must have the ability to provide control over the disease when a patient is suffering from moderate to severe atopic dermatitis. It has also been observed that at present, the market players have not been able to provide effective therapeutics to meet the increasing number of unmet needs. However, according to the market research and analysis, patients with atopic dermatitis do not respond to other treatments as they do with biologics, which targets adaptive immune responses
Overview of the global human respiratory syncytial virus drugs market
The global human respiratory syncytial virus (RSV) drugs market is anticipated to grow at a steady rate and post a CAGR of more than 4% during the forecast period. The increasing usage of novel diagnostic tools will drive the growth prospects for the global human respiratory syncytial virus drugs market until the end of 2020. Novel diagnostic tools are used to detect, screen, and evaluate individuals with respiratory syncytial virus (RSV). Some of the novel diagnostic methods include rapid diagnostic assays, RT-PCR assays, and serological tests. Also, the vendors and researchers are increasingly focusing on the development of novel diagnostic tests due to the rising demand for accurate diagnosis. For instance, Quidel offers the Lyra RSV + hMPV assay for the qualitative detection and identification of RSV. Such diagnostic tools deliver results equivalent to central laboratory standards within 70 minutes and are more effective and accurate. Other such products include Idylla Respiratory IFV-RSV Panel for the detection of various strains of RSV and influenza virus.
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as
Overview of the global alopecia drugs market
The global alopecia drugs market is anticipated to grow at a steady rate and will post a CAGR of more than 5% during the forecast period. The increasing popularity of off-label and over-the-counter (OTC) drugs will drive the growth prospects for the global alopecia drugs market during the forecast period. Off-label drugs are used extensively by the consumers because the exact therapy targeted at remission of alopecia is currently unavailable. For instance, AVODART is approved for the treatment of prostate cancer, but this drug is also used for the treatment of alopecia. Such drugs are used in the absence of any proven remission track and can be a threat to the market’s growth in the future. However, at present, the increasing use of off-label drugs is fuelling the sale of these drugs. Also, these drugs are being used for unapproved clinical indication or extension to a milder form of approved indication or extension to related conditions. For instance, alopecia market heavily uses spironolactone and cyclosporine, which are primarily approved for other indications.
In terms of geography, the Americas accounted for the maximum market share in 2015 because the US was the largest revenue contributor in the region. During the forecast period, the Americas will continue to dominate the market due to the increasing awareness about the disease and drugs in the region. Furthermore, the changing lifestyle of individuals is resulting in hormonal imbalances due to increased stress, consumption of junk food, and physical inactivity. Also, the increasing rate of hormonal imbalances in the region can cause disorders that will increase the consumption of drugs.
Competitive landscape and key vendors
The leading vendors of the market are investing extensively in R&D of new drugs because there are no effective treatment options available for
The market for treatments for infectious, rare, and orphan diseases is booming, and will continue to do so through the forecast period. The anti-infectives therapeutic segment has the most potential, as it has multiple first-in-class innovations, especially for emerging infectious diseases.
Additionally, the advent of novel therapeutics has revolutionized the treatment paradigm for some infectious diseases. The industry is focused on increasing pharmaceutical research and development activities to innovate and develop new products that can improve patient outcomes. This will continue to be the prime driver for this diversified therapeutic segment.
Despite the target population being smaller, drugs approved for orphan diseases remain revenue boosters for pharmaceutical companies. Key factors fueling the interest of pharmaceutical companies in including orphan drugs in their product portfolios include premium drug prices, high unmet need, extended market exclusivities, tax grants, and reduced timeframes for clinical development.